Information Density: GSK plc – Signal Evidence & AI Readability

[H1] Investors
[H2] GSK delivers first quarter 2026 results
Quarterly resultsListen to the webcast
[IMG: Luke Miels CEO]
Close video
[H2] Who we are
As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.​Purpose, strategy and cultureWhy invest in GSK?Respiratory, immunology and inflammation7mdeaths each year due to lung diseasesGo to respiratory, immunology and inflammationOncology~10mpeople die from cancer each yearGo to oncologyHIV40mpeople living with HIV globallyGo to HIVInfectious diseases1 in 7deaths globally caused by infectious diseaseGo to infectious diseasespreviousnextBehind the Science
[H2] Exploring how today's discoveries are shaping tomorrow's health
[H3] ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
[H3] Antibody-drug conjugates: Advancing the search for more targeted cancer treatment
[H3] Mapping disease at the cellular level: A single-cell revolution in drug discovery
[H3] Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus
[H3] 'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'
[H3] 'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'
[H3] 'Prevention is the best medicine to stop disease before it starts'
[H3] ‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it
[H3] ‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’
[H3] ‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options
previousnextRead our magazine
[H3] INVESTORS
We announced our first quarter 2026 results on Wednesday 29 AprilView latest results

[H1] Careers
[H2] Getting ahead of disease. It's personal.
At GSK, we all have our own personal motivations for wanting to get ahead of disease. And together, by uniting cutting-edge science, advanced technology, and our incredibly talented people, we're working towards positively impacting the health of 2.5 billion people by the end of this decade - and we invite you to join us on this journey.
[IMG: Angeles on the beach]
Close videoEnter job title hereEnter location hereSearch
[H2] Find out what it's like to work with us
[IMG: make a difference with us]
Make a difference with usMake a difference with usWith our innovation, scale and global partnerships, working with us presents a unique opportunity to impact the lives of billions.
[IMG: do your best with us]
Do your best work with usDo your best work with usTo get ahead of disease together, continuous growth and development are vital. At GSK you'll expand your skills and build valuable connections, enabling you to do your best work.
[IMG: be yourself]
Be yourself with usBe yourself with usWe've built an inclusive and supportive culture, so that you can pursue your professional goals without compromising on what matters most.previousnext
[H2]
2:10
[IMG: Meet Lais, researcher, proud daughter, global health champion]
Great place to work
[H2] Meet Lais: researcher, proud daughter, global health champion.
28 November 2025 2:11Great Place To Work
[H2] Meet Carolina: barrier breaker, innovation enabler, community builder.
18 September 2025 2:04
[H2] Meet Ama: pharmacist, patient advocate, nurturer.
31 July 2025 2:21
[H2] Meet Richard: tech innovator, future shaper, problem solver.
30 May 2025 1:06
[H2] Meet Victoria: inclusivity champion, proud nerd and immunology innovator.
15 April 2025 02:00
[H2] Meet Tom: a scientist with a personal motivation to get ahead of cancer.
15 January 2025 1:00
[H2] Meet Kelsey: a kayaker, team player and global health advocate.
18 October 2024 1:00
[H2] Meet Sarah and Martha: engineers supporting our renewable energy transition.
13 September 2024 1:00
[H2] Meet Zack: chemist, early riser and planet protector, working to reduce waste and energy use at GSK.
24 June 2024 1:01
[H2] Meet Ram: an engineer, athlete and proud father, helping to revolutionise vaccine manufacturing at GSK.
18 June 2024
[H2] Why join GSK?
2:48We bring together the best and brightest minds to be ambitious for our patients and help us make a lasting impact on the health of millions of people across the world.
There has never been a more exciting time for us. In a new era for human health what we do has never mattered more as we tackle some of healthcare’s biggest challenges to get ahead of disease together.
Life at GSKView video on YouTube
[H2] Together, we make GSK a great place to work
[IMG: Glassdoor best places to work logo]
Best places to work
[IMG: Best employers Europe 2025 logo]
Best employers Europe 2025
[IMG: Best employers for company culture 2025 logo]
Best employers for company culture 2025
[IMG: Science 2025 top employer logo]
Top Biotech and Pharma employer
[IMG: Fortune 100 best companies to work for]
Best companies to work for 2025previousnext
[H2] Talking about inclusion and support
04:11Inclusion and support
[H2] Allen, Tricia and Ryan talk about the importance of showing up for ourselves and each other
01 April 2026
[H2] You might also like
[IMG: experienced professionals working at a desk]
[H3] Experienced professionals
We want outstanding people who can help us improve the world’s health and get ahead of disease together
[IMG: Woman writing notes on a whiteboard while other employees watch]
[H3] Early careers
Our early careers programmes help you hit the ground running as you enter the world of work
[IMG: Lab worker smiling]
[H3] Inclusion
We embrace inclusion across our science, access to medicine and vaccines and our people and culture.

[H1] Company
[H2] We are GSK
We discover, develop and deliver medicines and vaccines to create value for patients and shareholders.Close videoScroll to explore
[H2]
Innovation to prevent and treat disease is at the heart of everything we do.We aim to positively impact the health of 2.5 billion people by the end of the decade.Our purpose, strategy and cultureGSK at a glanceResearch and development58medicines and vaccines in developmentInnovationGetting ahead of disease in70markets worldwideCareersOutstanding people66,800GSK peopleOutstanding peopleResponsible business2ndin the Access to Medicine Index among 20 of the world's largest pharmaceutical companiesResponsibilityPerformance£32.7bngroup turnover in 2025, AER 4% CER 7%InvestorspreviousnextBehind the Science
[H2] Exploring how today's discoveries are shaping tomorrow's health
[H3] ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
[H3] Antibody-drug conjugates: Advancing the search for more targeted cancer treatment
[H3] Mapping disease at the cellular level: A single-cell revolution in drug discovery
[H3] Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus
[H3] 'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'
[H3] 'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'
[H3] 'Prevention is the best medicine to stop disease before it starts'
[H3] ‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it
[H3] ‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’
[H3] ‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options
previousnextRead our magazine
[H2] You might also like
[IMG: GSK Tech Human Image]
[H3] Purpose, strategy and culture
At GSK we unite science, technology and talent to get ahead of disease together
[IMG: CFO Julie Brown talks to Board Director Charles Bancroft, behind stands Vishal Sikka, Liz Anderson]
[H3] Board of Directors and Executive Committee
GSK's Board oversees governance, strategy, risk and performance. Our CEO, supported by the Executive Committee, manages business operations.
[IMG: Lab worker carrying out a task]
[H3] GSK at a glance
We prioritise innovation in specialty medicines and vaccines to prevent and treat disease.

[H1] Behind the Science
[H2] Exploring how today's discoveries are shaping tomorrow's health
[IMG: Scientist works in a futurist vaccine laboratory for GSK]
Behind the Science Exploring how today's discoveries are shaping tomorrow's health Feature
[H3] ‘We’ve seen an explosion in computing power’: Using AI, machine learning and data to unlock the mysteries of disease
5 min read time
[IMG: Man in a server room]
Opinion
[H3] ‘How do we improve trust in prevention? The answer lies closer to home than you might think’
By Professor Heidi J. Larson - 9 min read time
[IMG: Healthcare professional shows patient information on device]
Feature
[H3] Antibody-drug conjugates: Advancing the search for more targeted cancer treatment
4 min read time
[IMG: Antibody Drug Conjugate]
Opinion
[H3] ‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’
By Hesham Abdullah - 3 min read time
[IMG: Two people holding hands]
[H3] ‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease
3 min read time
[IMG: Scientists use pipettes in laboratory]
Feature
[H3] Is it COVID-19, flu, or RSV? The symptoms to look out for – and how to tell the difference
5 min read time
[IMG: woman sneezing]
Feature
[H3] ‘We’ve seen an explosion in computing power’: Using AI, machine learning and data to unlock the mysteries of disease
5 min read time
[IMG: Man in a server room]
Opinion
[H3] ‘How do we improve trust in prevention? The answer lies closer to home than you might think’
By Professor Heidi J. Larson - 9 min read time
[IMG: Healthcare professional shows patient information on device]
Feature
[H3] Antibody-drug conjugates: Advancing the search for more targeted cancer treatment
4 min read time
[IMG: Antibody Drug Conjugate]
Opinion
[H3] ‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’
By Hesham Abdullah - 3 min read time
[IMG: Two people holding hands]
[H3] ‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease
3 min read time
[IMG: Scientists use pipettes in laboratory]
Feature
[H3] Is it COVID-19, flu, or RSV? The symptoms to look out for – and how to tell the difference
5 min read time
[IMG: woman sneezing]
[IMG: Podcast host Kat]
[H2] Podcasts
Welcome to Behind the Science with GSK, hosted by Dr. Kat Arney.Listen to the podcast now
[H2] Innovation videos
0:37
[IMG: Science explainer]
Science explainerWhat is RSV?previousnext 0:37Now playingScience explainerWhat is RSV? 1:45Now playingInnovation videoEosinophils: the missing link between symptoms, diagnosis and treatment? 0:35Now playingScience explainerWhat is an adjuvant? 0:32Now playingScience explainerHow can booster vaccines help against COVID-19? 0:39Now playingInnovation videoOur commitment to AMR 0:34Now playingInnovation videoDo we need more than one solution against COVID-19? 0:46Now playingScience explainerWhat is oncology cell therapy? 0:45Now playingScience explainerWhat is synthetic lethality? 0:48Now playingScience explainerWhat is multiple myeloma? 0:44Now playingScience explainerWhat is immuno-oncology? 0:36Now playingScience explainerWhat are monoclonal antibodies? 0:37Now playingScience explainerWhat is anaemia? 0:38Now playingScience explainerWhat is a PD-1 blocked agent? 0:41Now playingScience explainerWhat are variants? 0:37Now playingScience explainerWhat is RSV? 1:45Now playingInnovation videoEosinophils: the missing link between symptoms, diagnosis and treatment? 0:35Now playingScience explainerWhat is an adjuvant? 0:32Now playingScience explainerHow can booster vaccines help against COVID-19? 0:39Now playingInnovation videoOur commitment to AMR 0:34Now playingInnovation videoDo we need more than one solution against COVID-19? 0:46Now playingScience explainerWhat is oncology cell therapy? 0:45Now playingScience explainerWhat is synthetic lethality? 0:48Now playingScience explainerWhat is multiple myeloma? 0:44Now playingScience explainerWhat is immuno-oncology? 0:36Now playingScience explainerWhat are monoclonal antibodies? 0:37Now playingScience explainerWhat is anaemia? 0:38Now playingScience explainerWhat is a PD-1 blocked agent? 0:41Now playingScience explainerWhat are variants? 0:37Now playingScience explainerWhat is RSV? 1:45Now playingInnovation videoEosinophils: the missing link between symptoms, diagnosis and treatment? 0:35Now playingScience explainerWhat is an adjuvant? 0:32Now playingScience explainerHow can booster vaccines help against COVID-19? 0:39Now playingInnovation videoOur commitment to AMR 0:34Now playingInnovation videoDo we need more than one solution against COVID-19? 0:46Now playingScience explainerWhat is oncology cell therapy? 0:45Now playingScience explainerWhat is synthetic lethality? 0:48Now playingScience explainerWhat is multiple myeloma? 0:44Now playingScience explainerWhat is immuno-oncology? 0:36Now playingScience explainerWhat are monoclonal antibodies? 0:37Now playingScience explainerWhat is anaemia? 0:38Now playingScience explainerWhat is a PD-1 blocked agent? 0:41Now playingScience explainerWhat are variants?

[H1] Innovation
[H2] Bringing innovation to patients, better and faster
We’re harnessing the power of advanced tech, combined with our deep understanding of the science of the immune system, to develop new medicines and vaccines.Learn how we use Tech
[IMG: data and DNA image]
Close videoScroll to explore
[H2] Innovating to meet patient need
We prevent and treat disease with innovation in specialty medicines and vaccines. Our R&D approach combines our scientific focus on the immune system with the use of advanced technologies.
We’re working to deliver a new generation of differentiated medicines and vaccines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains: respiratory, immunology and inflammation; oncology, HIV; and infectious diseases.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
Discover our R&D approachThere’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.
[IMG: Tony Wood]
Tony WoodChief Scientific Officer
[H2] How we prevent and treat disease
[IMG: older couple working together in their garden]
Power of prevention
[IMG: Scientists sorting samples in the search for cure cure HIV]
Partnerships to deliver what matters
[IMG: Equipment Assembly Respiratory Medicine]
Harnessing advanced technologiespreviousnext
[H2] Our pipeline
We invest heavily in our industry-leading pipeline of potential specialty medicines and vaccinesAssets58Medicines and vaccines in the pipeline Research & development£6.6bnR&D investment in 2025Approvals5Major approvals in 2025Pipeline15Scale opportunities in our pipelinepreviousnextBehind the Science
[H2] Exploring how today's discoveries are shaping tomorrow's health
[H3] ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
[H3] Antibody-drug conjugates: Advancing the search for more targeted cancer treatment
[H3] Mapping disease at the cellular level: A single-cell revolution in drug discovery
[H3] Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus
[H3] 'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'
[H3] 'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'
[H3] 'Prevention is the best medicine to stop disease before it starts'
[H3] ‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it
[H3] ‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’
[H3] ‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options
previousnextRead our magazine
[IMG: Tony Wood]
[H2]
Meet the world-leading scientists who are working to bring innovative medicines and vaccines to patients.Learn more about our leading scientists
[H2] You might also like
[IMG: Two lab workers carrying out tasks]
[H3] Therapeutic areas
Our portfolio and pipeline is focused on respiratory, immunology and inflammation; oncology; HIV; and infectious diseases
[IMG: USA lab wide shot of two people working in lab]
[H3] Research and development approach
Our R&D focuses on the science of the immune system and advanced technologies
[IMG: Man looks at data on computer screens]
[H3] Tech
Tech is revolutionising how we develop medicines and vaccines, streamline clinical trials, optimise supply chains, enhance patient care

[H1] Products
[H2] Our products
Learn more about our product portfolio and how we’re prioritising specialty medicines and vaccines.Our product areasProducts A-Z
[IMG: Lab worker carrying out a task]
Close videoScroll to explore
[H2] Our product areas
[IMG: HIV Science Image]
Specialty medicinesSpecialty medicinesOur specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus.
[IMG: Shingles Science Image]
VaccinesVaccinesOur portfolio of vaccines is one of the broadest in the industry. We deliver hundreds of millions of vaccine doses every year. Our vaccines portfolio targets infectious diseases from birth throughout adulthood.
[IMG: Escherichia Coli (E. Coli) Bacteria Science Image]
General medicinesGeneral medicinesGeneral medicines are usually prescribed in primary care or community settings by general healthcare practitioners. General medicines include inhalers for asthma and COPD to antibiotics. Every day, our general medicines make life better for millions of people all over the world.previousnextView our product areas
[H2] Our medicines and vaccines
Getting ahead means preventing disease as well as treating it. Our R&D focus is to deliver new medicines and vaccines using the science of the immune system and advanced technologies to impact health at scale.33Medicine and vaccine manufacturing sites in our global network1.64bnPacks of medicines delivered in 2025389mVaccine doses delivered in 2025100Our general medicines reach people in more than 100 countriespreviousnextBehind the Science
[H2] Exploring how today's discoveries are shaping tomorrow's health
[H3] ‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
[H3] Antibody-drug conjugates: Advancing the search for more targeted cancer treatment
[H3] Mapping disease at the cellular level: A single-cell revolution in drug discovery
[H3] Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus
[H3] 'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'
[H3] 'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'
[H3] 'Prevention is the best medicine to stop disease before it starts'
[H3] ‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it
[H3] ‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’
[H3] ‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options
previousnextRead our magazine
[H2] You might also like
[IMG: USA lab wide shot of two people working in lab]
[H3] Research and development approach
Our R&D focuses on the science of the immune system and advanced technologies
[IMG: Man looks at data on computer screens]
[H3] Tech
Tech is revolutionising how we develop medicines and vaccines, streamline clinical trials, optimise supply chains, enhance patient care
[IMG: Tony Wood sitting]
[H3] Our leading scientists
Meet the world-leading scientists who are working to bring innovative medicines and vaccines to patients